Cipla Q2 Net Profit Falls 35% Amid US Sales Decline, India Revenue Grows
Cipla reported a 35% year-on-year decline in consolidated net profit to around Rs 877-878 crore for Q2 FY27, with revenue falling 1-2.4% to approximately Rs 7,368-7,404 crore. The decline was driven by weaker sales in its North American business, particularly due to competition affecting generic Revlimid, while domestic Indian revenue grew about 12%. Expenses rose year-on-year, impacting margins. Cipla expects growth in the US from upcoming respiratory product launches and aims for a $1 billion annual revenue run rate in North America by fiscal year-end, despite cost pressures from geopolitical tensions.
First-hand measurement across 11 sources
We measured how 11 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (49/100). Lens Score 31/100.
Outlets measured: moneycontrol, businessstandard, businessstandard, news18, economictimes, economictimes, freepressjournal, thefinancialexpress, and 3 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment ranged widely across outlets — from 35/100 to 75/100 — a sign the coverage itself was contested, not just reported.
Coverage timeline
economictimes broke this story on 27 Oct, 04:33 am. Other outlets followed.